Bayer expands: Japan-Lizenz for potential herbal medicine candidates – Aktietiefer | 19.11.24

The Mittel aficamten is intended for the treatment of patients with hypertrophic cardiomyopathy (HCM), one of the cerebral hemorrhages, infected. Bayer became the phase 3 study in Japanese patients with obstructive HCM machines, which ended up in one of the pharmaceutical solutions.

Bayer has paid cytokinetics 50 million euros and 90 million euros for the market effort. The expenditure for a period of 490 million euros would fail, when Bayer attempted to find a solution for the delivery of a loan to the Japanese American economy. The industry’s marketing in the US and Europe is in the field of cytokinetics.

The Bayer promotion gives in XETRA-Handel a duration of 0.57 Prozent auf 20.10 Euro nach.

DJG/rio/mgo

DOW JONES